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The Association between Invasive
Group A Streptococcal Diseases and
Viral Respiratory Tract Infections
Andrea L. Herrera, Victor C. Huber and Michael S. Chaussee*
Division of Basic Biomedical Sciences, The Sanford School of Medicine of the University of South Dakota, Vermillion, SD, USA
Viral infections of the upper respiratory tract are associated with a variety of invasive
diseases caused by Streptococcus pyogenes, the group A streptococcus, including
pneumonia, necrotizing fasciitis, toxic shock syndrome, and bacteremia. While these
polymicrobial infections, or superinfections, are complex, progress has been made in
understanding the molecular basis of disease. Areas of investigation have included the
characterization of virus-induced changes in innate immunity, differences in bacterial
adherence and internalization following viral infection, and the efficacy of vaccines in
mitigating the morbidity and mortality of superinfections. Here, we briefly summarize
viral-S. pyogenes superinfections with an emphasis on those affiliated with influenza
viruses.
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INTRODUCTION
The study of microbial pathogenesis typically examines a single pathogen in an experimental
system. The reductionist approach has proven to be highly informative and forms the foundation
of our understanding of pathogenesis. Nonetheless, humans are often exposed to an assortment
of viral and bacterial pathogens and the factors determining the outcome of these host-pathogen
interactions are less well characterized. Viral infections complicated by a concurrent, or subsequent,
bacterial infection are known as coinfections or superinfections, respectively. Due to synergistic
effects, the mortality of these infections is often greater than that of either the virus or the bacteria
alone (Morens and Taubenberger, 2015).
Streptococcus pyogenes, the group A streptococcus (GAS), can colonize humans
asymptomatically or cause infections of the skin and pharynx. In severe cases, the gram-positive
pathogen can cause a variety of life threatening invasive diseases (iGAS diseases) including
bacteremia, toxic shock syndrome, pneumonia, and necrotizing fasciitis (the so-called “flesh
eating disease”). GAS causes approximately 700 million infections annually, including 1.8 million
invasive infections. The mortality rate of these infections is ∼20% (Carapetis et al., 2005),
despite the availability of antibiotics that are effective ex vivo. Here we briefly summarize the
epidemiological reports supporting the idea that upper respiratory tract viral infections contribute
to the development of iGAS diseases and review studies aimed at identifying the molecular
underpinnings of viral-GAS pathogenesis.
THE CONTRIBUTION OF VARICELLA, MORBILLA VIRUS, AND
EPSTEIN–BARR VIRUS TO iGAS DISEASES
The association between chickenpox and GAS necrotizing fasciitis was described as early as the
nineteenth century and varicella continues to be an important contributor to iGAS diseases among
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children, which is most evident in regions of the world that
choose not to vaccinate against chickenpox or that lack the
resources to do so (Wilson et al., 1995; Schreck et al., 1996).
GAS is the most common bacterial cause of varicella coinfections
(Aebi et al., 1996), which typically results in necrotizing fasciitis,
bacteremia, and toxic shock syndrome. Usually these diseases
occur as the result of infected skin lesions, which provide
portals for bacterial entry into the blood. However, varicella-
GAS superinfections can also occur, albeit rarely, when varicella
skin lesions are not apparent suggesting that the viral infection
causes systemic decreases in innate immunity (Laskey et al., 2000;
Sivakumar and Latifi, 2008). Prior to the use of the vaccine,
the incidence of varicella-GAS coinfections was estimated to
be between 15 and 36% (Laupland et al., 2000; Zachariadou
et al., 2014). Results of a study that spanned both the pre and
post-varicella vaccination periods (1993–2001) showed that the
incidence of these coinfections declined from 27% prior to 1995
to just 2% after the availability of the vaccine (Patel et al., 2004).
Both GAS and Epstein–Barr virus (EBV) are common causes
of pharyngitis. Two studies focused on patients 25 years-of-age or
younger and determined the incidence of EBV-GAS coinfection
to be 18 and 29% (Henke et al., 1973; Rush and Simon, 2003).
In contrast, <3% of college students with EBV were also infected
with GAS (Chretien and Esswein, 1976).While there are sporadic
and infrequent reports of children with infectious mononucleosis
developing iGAS diseases, including streptococcal toxic shock
syndrome (Pontes and Antunes, 2004) and GAS bacteremia
(DuBois and Baehner, 1979), a causal role for EBV in iGAS
diseases remains unclear (Watanabe et al., 2012).
Measles virus (MV) infection can also enhance host
susceptibility to bacterial infections (de Vries et al., 2012). While
the incidence of MV-GAS coinfections is currently low, this
has not always been the case. In 1917, an epidemic of severe
GAS diseases coincided with a measles epidemic among U.S.
Army personnel resulting in bronchopneumonia, empyema, and
bacteremia, which were associated with significant mortality
(Morens and Taubenberger, 2015). While GAS is currently a
relatively uncommon cause of MV superinfections, sporadic
cases still occur (Gremillion and Crawford, 1981; Duke and
Mgone, 2003; Gahr et al., 2014).
THE CONTRIBUTION OF INFLUENZA TO
iGAS DISEASES
The most thoroughly characterized bacterial superinfections
are those involving the influenza virus (McCullers and Rehg,
2002; Peltola and McCullers, 2004). Streptococcus pneumoniae,
Staphylococcus aureus, Haemophilus influenzae, and GAS are
causes of “excess mortality” due to influenza coinfections and
superinfections (Peltola and McCullers, 2004; Brundage, 2006),
which were first described nearly a century ago (Laennec, 1923).
An analysis of lung biopsies from the 1918 influenza pandemic
revealed that S. pneumoniae and GAS were the most frequently
observed bacteria and together contributed substantially to the
deaths of approximately 50 million people (Morens and Fauci,
2007). The surprisingly high incidence of cases involving GAS
was likely due to the circulation of particularly virulent GAS
strains and high carriage rate during this time (Morens and
Taubenberger, 2015). More recently during the 2009 H1N1
influenza pandemic, 27% of fatalities among people with
laboratory confirmed IAV-bacterial coinfections were caused by
GAS1. A report of 10 patients in California with laboratory
confirmed H1N1-GAS infections during this pandemic revealed
that despite treating at least 6 patients with both antivirals and
antibiotics, 7 of the 10 patients died and the median age of the
deceased was 37 (Jean et al., 2010).
In addition to these cases in the US, iGAS diseases associated
with IAV occurWorldwide. In England, the incidence of all iGAS
diseases increased by 26% between July 2009 and January 2011
with the highest increase reported in December 2010, which
was attributed to an increase in influenza during the same time
period (Zakikhany et al., 2011). A retrospective study conducted
in France found that one third of children infected with GAS also
had laboratory confirmed influenza infection (Parola et al., 2011).
In Israel during the 2009–2010 influenza pandemic there was an
increase in GAS bacteremia (Tasher et al., 2011). Similarly, the
incidence of iGAS diseases in Sweden increasedmarkedly in 2012
compared to previous years, which was attributed to an increase
in respiratory viral infections, particularly influenza (Darenberg
et al., 2013).
A study of military recruits in the U.S. provides a different
perspective illustrating the contribution of IAV to GAS diseases.
The recruits were less likely to experience any GAS disease if
they were vaccinated against influenza compared to unvaccinated
controls, and protection against GAS diseases ranged from 50 to
77% depending on the year of the study (Lee et al., 2008).
In addition to IAV, influenza B virus (IBV) is associated
with iGAS diseases (Aebi et al., 2010). In a study conducted in
Canada, 8% of patients with iGAS diseases occurring between
1996 and 2008 were also infected with IBV (Allard et al., 2012).
In a study conducted in England, 14 of 19 cases of iGAS
diseases including bacteremia, septic arthritis, endometritis, and
pneumonia had evidence of a previous influenza-like infection
and 26% had laboratory confirmed influenza infections, mostly
IBV. Significantly, ten of the patients died even though 9 of those
10 were being treated with antibiotics that are effective against
GAS ex vivo (Scaber et al., 2011).
Collectively, these clinical observations indicate that a
substantial number of iGAS diseases are associated with
influenza. Moreover, despite the availability of influenza vaccines,
the practice of prophylactically treating severely ill influenza
patients with antibiotics (Mandell et al., 2007), and the
fact that all isolates of GAS are sensitive to penicillin ex
vivo, the mortality rate of influenza-GAS superinfections is
substantial.
MECHANISMS OF IAV-GAS
SUPERINFECTION
The effect of influenza virus infection on host susceptibility
to bacterial infections has been most thoroughly studied with
1Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic
influenza A (H1N1) - United States, May-August 2009. Morb. Mortal. Wkly. Rep.
58, 1071–1074.
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S. pneumoniae and several excellent reviews on this topic
are available (McCullers, 2006, 2014; Metzger and Sun, 2013;
Rynda-Apple et al., 2015). Influenza infections increase host
susceptibility to bacterial infections in a variety of ways including
an increase in bacterial adherence after the removal of sialic acid
from respiratory cells by viral neuraminidase (McCullers and
Bartmess, 2003; McCullers, 2014); destruction of the mucocilliary
escalator by viral induced lysis of respiratory epithelial cells
(Ohashi et al., 1991; Pittet et al., 2010); decreased expression
by alveolar macrophages of the scavenger receptor MARCO
following influenza induction of IFN-γ (Sun and Metzger, 2008);
depletion of resident alveolar macrophages following influenza
infection (Ghoneim et al., 2013). As a result, macrophage-
mediated clearance of bacteria is diminished.
Comparatively little is known about the host-pathogen
interactions of IAV-GAS superinfection; however, the areas
that have been investigated include the development of
murine models of superinfection, characterization of viral-
induced changes in bacterial adherence and internalization, and
assessments of the efficacy of vaccines targeting either the virus
or bacteria in decreasing the morbidity and mortality associated
with superinfections.
Murine Models of IAV-GAS Superinfection
Murine models of IAV-GAS superinfection typically use sub-
lethal intranasal inoculations of IAV and GAS, which are
separated by 2–7 days. These studies are summarized in Table 1.
As is likely the case with human disease, the outcome of murine
IAV-GAS infections varies greatly depending on the specific
viral and bacterial strains used in the study. In one case, the
outcome of an IAV-GAS coinfection was compared between
mice inoculated with isolates of GAS from patients with toxic
shock syndrome and those from non-invasive infections using
an interval of 2 days between viral and bacterial inoculations
(Okamoto et al., 2003). Coinfection with isolates from cases of
toxic shock syndrome resulted in the death of 80–95% of themice
while inoculation with the same dose of the isolates in the absence
of antecedent viral infection resulted in no mortality. In contrast,
when mice were coinfected with GAS isolates from non-invasive
infections the mortality was <30% (Okamoto et al., 2003). A
subsequent study used a 5 day interval between IAV and GAS
inoculations, which allows mice time to begin to recover from
the viral infection prior to being infected with bacteria. Using
this model, the contribution of eight different isolates of IAV
to the outcome of superinfection was determined with a single
isolate of GAS (Weeks-Gorospe et al., 2012). Themortality varied
between 100 and 20% indicating that the outcome of IAV-GAS
superinfections is also affected by the particular type of influenza
virus (Weeks-Gorospe et al., 2012). Together, the results indicate
that the severity of IAV-GAS superinfections is likely to vary
considerably depending on the specific types of IAV and GAS
circulating in the population.
The mortality of IAV-GAS superinfections in mice is due,
in part, to increased persistence of the bacteria in the lungs
of superinfected mice compared to mice infected with only
GAS (Chaussee et al., 2011). Persistence is associated with
subsequent bacteremia and multi-organ infection. As a result of TA
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dissemination, ∼10% of superinfected mice develop necrotizing
fasciitis (Okamoto et al., 2003).
Since the respiratory tract is altered during IAV infection,
including changes in cell types, cytokine milieu, host protein
composition and abundance, and endothelial and effector cell
functions, it is of interest to know if GAS virulence factors
important in a GASmonoinfection are similarly important in the
context of a coinfection or superinfection. To address this issue,
a serotype M1 strain of GAS and several mutant derivatives were
analyzed with a murine H1N1 superinfection model (Okamoto
et al., 2004b). Strains included those with mutations in the hasA
gene (encoding the first enzyme involved in the synthesis of
the hyaluronic acid capsule), slo (encoding the secreted thiol-
activated cytolysin SLO), speB (encoding a secreted cysteine
protease), sagA (encoding a secreted cytolysin SLS), and mga
(encoding a global transcriptional regulatory protein; Okamoto
et al., 2004b). Only 10% of mice coinfected with the parental
GAS strain survived. In contrast, between 40 and 80% of mice
coinfected with the mutant derivatives survived. The hasA gene
had the most significant contribution to disease, which was
attributed to decreased bacterial adherence due to the loss of the
capsule (Okamoto et al., 2004b), which is an adhesion (Schrager
et al., 1998). However, the capsule is also antiphagocytic, which
likely contributed to the ability of the parental strain, but not the
hasA mutant, to persist in the lungs of coinfected mice. In this
respect, the hasA mutant had the fewest bacteria in the lungs of
superinfected mice 24 h after inoculation compared to the wild-
type strain and the other mutants. The coinfection studies were
completed using an interval of 2 days between viral and bacterial
inoculations (Okamoto et al., 2004b). The results indicate that
virulence factors important in a monoinfection also contribute to
coinfection and it will be of interest to determine if similar results
are obtained using a superinfection model with a longer interval
between viral and bacterial inoculations.
Adherence and Internalization
IAV infection increases the abundance of fibrinogen (Fg) in the
respiratory tract beginning approximately 4 days after infection
(Keller et al., 2006). The binding of GAS to Fg has been
recognized for decades as being important for GAS adherence
and internalization within host epithelial cells and for conferring
resistance to phagocytosis (Cunningham, 2000). IAV infection
enhanced the adherence of GAS to culturedMadin–Darby canine
kidney (MDCK) cells in an Fg-dependent manner (Sanford et al.,
1982). The finding was confirmed by a subsequent study showing
that both bacterial adherence and internalization were enhanced
in cells infected with IAV, and that the effect was also dependent
on the GASM protein, which binds to a variety of host proteins
including Fg (Hafez et al., 2010). In addition to Fg, Streptococcus
dysgalactiae binds directly to IAV hemagglutinin (HA) localized
to the surface of infected cells. Binding was diminished by the
addition of GAS, which indicated that GAS was also likely to bind
directly to viral HA (Pan et al., 1979). In this regard, IAV infection
of cultured cells (A549 and MDCK) increased GAS adherence
and internalization compared to uninfected cells (Okamoto et al.,
2003) and GAS bound directly to progeny virus budding from
infected cells, presumably by binding to viral HA (Okamoto
et al., 2003). Moreover, treating superinfected mice intravenously
with antibodies against HA decreased the number of streptococci
in the lungs as well as other organs and mortality (Okamoto
et al., 2003). Similarly the adherence and internalization of a
GAS serotype M6 isolate (JRS4) to MDCK cells was enhanced
4- and 20-fold, respectively, in viral infected cells compared
to uninfected cells (Hafez et al., 2010). Both adherence and
internalization were dependent on the M6 protein, and both
were enhanced by host Fg and fibronectin (Fn) (Hafez et al.,
2010).
The influenza neuraminidase cleaves sialic acid, which
exposes host proteins involved in pneumococcal adherence
(McCullers and Bartmess, 2003). Neuraminidase also stimulates
the expression of bacterial receptors by activating TGF-β (Li
et al., 2015), which also increases the production of Fn (Schultz-
Cherry and Hinshaw, 1996). Similar to Fg, Fn is an important
ligand for GAS adherence (Beachey and Courtney, 1989) and
internalization (Chaussee et al., 2000; Wang et al., 2006). Using
TGF-β knockout mice, Li et al. found that GAS colonization of
the lungs 3 days after IAV infection was less than that observed
with wild-type mice (Li et al., 2015). Thus several studies using
a variety of different isolates of virus and bacteria indicate that
IAV infection increases both GAS adherence and internalization
by binding to viral HA on the infected cell surface and following
increases in the abundance of, and access to, bacterial receptors
and the GAS ligands Fg and Fn.
Vaccination
Vaccination of mice against IAV provides significant protection
against mortality from GAS secondary infections (Okamoto
et al., 2004a; Chaussee et al., 2011). In one study, mice were
vaccinated against influenza and subsequently infected with an
H1N1 virus 2 days prior to infection with GAS; only 15% of
unvaccinated mice survived compared to 78% of vaccinated
mice (Okamoto et al., 2004a). A subsequent study compared
the efficacy of live attenuated and killed influenza vaccines in a
superinfection model in which mice were inoculated intranasally
with a normally sub-lethal dose of GAS 7 days after IAV infection
(Chaussee et al., 2011). Morbidity (measured by weight loss)
following IAV infection was undetectable amongmice vaccinated
with either formulation, consistent with protection against the
virus (Chaussee et al., 2011). Nonetheless, 22 and 33% of mice
receiving the attenuated or killed vaccine, respectively died as
a result of GAS superinfection. Thus, the influenza vaccines
prevented viral illness and decreased the mortality associated
with IAV-GAS superinfections; however, they did not provide
sterilizing immunity nor did they abrogate mortality. The results
suggest that IAV infection or exposure, even among vaccinated
people, may still contribute to the incidence of iGAS diseases.
A related study examined the effectiveness of vaccinating
against GAS using a hexavalent polypeptide corresponding
to surface localizedM proteins (Dale, 1999). In contrast to
vaccination against influenza and despite signs of illness after
IAV infection, vaccinated mice were completely protected from
mortality (Klonoski et al., 2014). One possible explanation for
the difference in protection between influenza vaccines and
the GAS vaccine is that vaccination against GAS may confer
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the host with the ability to clear the bacteria by an antibody-
dependent mechanism that is not compromised by antecedent
IAV infection. In contrast, following vaccination against IAV
viral exposure may still impair host defenses sufficiently to
promote bacterial superinfection, even in the absence of a
clinically apparent viral infection. Interestingly, a recent report
using a conjugate vaccine against S. pneumoniae showed that
this vaccine did not result in 100% protection as obtained
with the anti-M protein vaccine (Metzger et al., 2015). This
indicates that there is still much to learn regarding the differences
in the pathogenesis of IAV-bacterial superinfections and the
contributions of vaccine-induced immunity in the context of
polymicrobial infections. Future studies focused on defining
the mechanisms of vaccine-induced protection will aid in the
interpretation of these observations and guide the design of new
therapeutic strategies to mitigate the morbidity and mortality of
IAV superinfections.
SUMMARY
GAS causes several life threatening invasive diseases including
pneumonia, bacteremia, necrotizing fasciitis, and toxic shock
syndrome. Decades of study with GAS in monoculture and
withmonoinfected animal models has yielded significant insights
into the virulence factors and host responses that contribute to
invasive diseases (Cunningham, 2000; Fieber and Kovarik, 2014;
Walker et al., 2014). Similarly, genomic studies conducted during
the past decade have led to insights into the genetic characteristics
of GAS isolates from invasive infections (Musser and Shelburne,
2009). A less well understood contributor to iGAS diseases is
antecedent, or concurrent, viral infection of the upper respiratory
tract. Epidemiological studies and clinical reports support the
idea that several viruses, and particularly influenza, increase
the incidence of iGAS diseases. Although comparatively little is
known about the molecular bases underlying the observations,
virus-induced changes in bacterial adherence and effector
cell-mediated clearance appear to be particularly important.
Future studies will likely identify additional host and bacterial
factors important in the development of viral associated iGAS
diseases and polymicrobial diseases in general. Such knowledge
is especially important in the design of new strategies to
control the mortality of influenza-GAS superinfections, which
is significant despite the availability of influenza vaccines, anti-
viral treatments, and the ex vivo susceptibility of GAS to
penicillin.
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